Accurate detection of PIK3CA mutations is essential for personalizing breast cancer treatment, particularly with ...
"We hope our findings will help women better understand their risk of developing the disease across the course of life, so that they can make informed, individualized decisions about screening and ...
Clairity, Inc., a digital health innovator advancing AI-driven healthcare solutions, has received U.S. Food and Drug Administration (FDA) De Novo authorization for CLAIRITY BREAST, a novel, ...
Platform can help predict a woman's 5-year risk for developing breast cancer by analyzing routine mammograms. HealthDay News — The US Food and Drug Administration has granted de novo authorization to ...
n this study, 773 untreated breast cancer patients from all over China were collected and followed up for at least 5 years. We obtained clinical data from 773 cases, RNA sequencing data from 752 cases ...
Areas of Uncertainty in Pancreatic Cancer Surveillance: A Survey Across the International Pancreatic Cancer Early Detection (PRECEDE) Consortium Breast and Ovarian Analysis of Disease Incidence and ...
Startup Clairity scored a green light from the FDA for the agency's first artificial intelligence tool designed to predict five-year breast cancer risk from a routine screening mammogram. According to ...
Clairity, Inc., a digital health innovator advancing AI-driven healthcare solutions, has received U.S. Food and Drug Administration (FDA) De Novo authorization for CLAIRITY BREAST, a novel, ...
Breast cancer is the most common cancer among women, with over 2.3 million new cases diagnosed each year. Traditional ...
The FDA granted de novo authorization to the first artificial intelligence (AI) program to support breast cancer risk prediction from screening mammograms. The program, called Clairity Breast, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results